AlzeCure Pharma AB (publ) (STO:ALZCUR)
Sweden · Delayed Price · Currency is SEK 1.695
-0.025 (-1.45%)
Mar 20, 2026, 5:22 PM CET
AlzeCure Pharma AB Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
11
Market Cap
194.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Magle Chemoswed Holding AB | 300.49M |
| Sprint Bioscience AB | 167.17M |
| Xbrane Biopharma AB | 152.35M |
| IRLAB Therapeutics AB | 57.46M |
| Elicera Therapeutics AB | 10.86M |
| NextCell Pharma AB | 9.83M |
| Xintela AB | 2.28M |
| Lipum AB | 1.93M |